Brett A. Grimaud - 23 Sep 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: SVP, GEN COUNSEL AND SECRETARY
Issuer ticker: TBPH
Reported as of: 23 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Sep 2026, 20:23:05 UTC
Prior SEC filing: 24 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Brett A Grimaud

Key filing fact

Brett A. Grimaud filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 24 Sep 2026.

Key facts

This page summarizes Brett A. Grimaud's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 24 Sep 2026, 20:23.

Change

Previous filing in this sequence was filed on 24 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001966698 Primary reporting owner

Grimaud Brett A.

Relationship: SVP, GEN COUNSEL AND SECRETARY
Address: C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO
Signature: /s/ Brett A Grimaud
Signature date: 24 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -223,917
Change %: -63%
Price
Shares after: 131,251
Date: 23 Sep 2026
Ownership: Direct
Footnotes: F1

TBPH transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -107,812
Change %: -82%
Price
Shares after: 23,439
Date: 23 Sep 2026
Ownership: Direct
Footnotes: F2

TBPH transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -23,439
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Brett A. Grimaud is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

Footnote F2

At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

Footnote F3

As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.